DKSH Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DKSH.SW research report →
Price Chart
About the company
DKSH Holding AG provides various market expansion services in Thailand, Greater China, Malaysia, Singapore, rest of the Asia Pacific, and internationally. The company offers sourcing, market insights, marketing, sales, e-Commerce, distribution, logistics, and after sales services. It operates through four segments: Healthcare, Consumer Goods, Performance Materials, and Technology.
- CEO
- Stefan Butz
- IPO
- 2012
- Employees
- 24,942
- HQ
- Zurich, ZH, CH
Get TickerSpark's AI analysis on DKSH.SW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.32B
- P/E
- 19.64
- Fwd P/E
- 18.19
- PEG
- 1.55
- P/S
- 0.39
- P/B
- 2.44
- EV/EBITDA
- 10.03
- Div Yield
- 3.77%
- Gross Margin
- 6.01%
- Op Margin
- 2.75%
- Net Margin
- 1.93%
- ROE
- 12.24%
- ROIC
- 8.27%
Latest fiscal year · YoY change
- Revenue
- $11.07B-0.2%
- Gross Profit
- $746.90M-54.6%
- Op Income
- $316.60M
- Net Income
- $202.90M-5.5%
- EPS
- $3.12-5.5%
- OCF Growth
- -11.8%
- FCF Growth
- -12.3%
- 52W High
- $69.70
- 52W Low
- $52.40
- 50D MA
- $65.21
- 200D MA
- $60.39
- Beta
- 0.44
- RSI (14)
- 46
- Avg Volume
- 71.97K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
DKSH reported solid first-half 2026 growth and cash generation, with higher EPS and an upbeat full-year outlook despite FX and margin investment pressures.· July 17, 2026
- Net sales rose 4.9% to CHF 5.5 billion and Core EBIT increased 3.6% to CHF 163.4 million; EPS was CHF 1.56, up 10.6% after the company corrected an initial calculation error.
- Free cash flow was CHF 147.7 million with cash conversion of 130.8%, above the company’s target for the fourth straight year.
- Healthcare and Consumer Goods grew well, while Performance Materials and Technology also contributed; Technology saw the sharpest profit jump on data center demand.
- Management said group Core EBIT margin was 3.0%, down 10 bps year over year, mainly due to FX and temporary investment/ramp-up effects.
- DKSH reconfirmed full-year 2026 Core EBIT is expected to be higher than 2025 and said it is confident in a stronger second half, supported by M&A and healthcare acceleration.
DKSH said first-half 2026 net sales increased 4.9% to CHF 5.5 billion, Core EBIT rose 3.6% to CHF 163.4 million, and corrected EPS was CHF 1.56 per share, up 10.6%. Core EBIT margin was 3.0%, down 10 basis points year over year, with FX and temporary investment/mix effects cited as the main reasons. Core profit after tax was CHF 112.9 million, up 12.9%, and free cash flow was CHF 147.7 million with cash conversion of 130.8%. For the full year, management expects Core EBIT 2026 to be higher than 2025; they also said announced/completed acquisitions should add about one percentage point to 2026 net sales growth, tax rate should stay within 27% to 29%, and capex should remain at 0.3% to 0.4% of net sales.
CEO Stefan Butz framed the half as evidence of DKSH’s resilient business model and consistent execution, saying the company delivered accelerated organic growth, strong cash flow, and higher EPS despite global uncertainty. He emphasized four strategic priorities: growth, margin expansion, M&A, and building future growth engines, including AI and data-center-related capabilities. Tone-wise, he was confident and constructive, repeatedly saying the company is well positioned for a stronger second half and longer-term margin expansion.
CFO Ido Wallach highlighted that growth was broad-based across all four business units and that Core EBIT rose for the 11th consecutive first half versus the prior year. He attributed the lower Core EBIT margin primarily to translational FX, which he quantified at CHF 12 million or 7.1% on Core EBIT, and to temporary ramp-up investments and mix effects. He also pointed to strong capital discipline: working capital at 7.8% of annualized net sales, capex at 0.3% of net sales, Core ROIC at 18.7%, equity ratio at 31.9%, and a minor net debt position of CHF 10.8 million.
Analysts focused on second-half EBIT drivers, especially healthcare margin pressure, tech contribution from associates/data-center projects, consumer-margin recovery, FX, and M&A. Management said healthcare’s top-line could accelerate by about 2% on top of recent roughly 4% growth, but upfront investment for new products will continue and margins may be slightly pressured in the near term before improving over time. On tech, management said associate profit is expected to be a double-digit absolute number by year-end, and on consumer they guided second-half margin to be similar to last year’s second half while noting pricing and promotional pressure should ease somewhat.
The bull case is that DKSH is still growing faster than GDP, with broad-based sales momentum and particularly strong growth in Healthcare, Consumer Goods, and Technology. Management also sees a meaningful pipeline of signed or near-signed healthcare contracts, continued data-center demand, and a healthy M&A pipeline that could support a stronger second half and higher 2026 EBIT.
The main risks discussed were FX headwinds, temporary margin pressure from healthcare ramp-up investments, and promotional pricing pressure in Consumer Goods. Management also acknowledged that some performance material markets remain more challenging, North America is tougher, and the second-half outcome depends on execution, market conditions, and whether delays affect data-center and M&A contributions.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 54.5%
- Shares Outstanding
- 65.03M
- Float Shares
- 35.45M
Held by 253 ETFs
Biggest fund positions in DKSH.SW by dollar value.
Our DKSH.SW coverage
Recent articles, reports, and earnings notes.
No research on DKSH.SW yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DKSH.SW report →